Considering Titanium Dioxide Regulatory Changes

News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume 2021 eBook
Issue 3

EFSA’s evaluation of risk in food products raises implications for drug product formulations.

titanium dioxide

Kateryna Kon/Adobe.Stock.com

Titanium dioxide is widely used for adding opacity and brightness in many products. A May 2021 evaluation from the European Food Safety Authority (EFSA), which declared that titanium dioxide is unsafe for food products, alarmed other industries that rely on the ingredient. Although changes are not required in pharmaceutical products, some supplement and drug manufacturers and their suppliers have considered potential alternatives. 

Read this article in Pharmaceutical Technology’s Regulatory Sourcebook eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 8-9

Citation

When referring to this article, please cite it as J. Markarian, “Considering Titanium Dioxide Regulatory Changes,” Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development